熱門資訊> 正文
蒂齐亚纳因多发性硬化症治疗研究的积极结果而上涨
2025-05-06 21:08
- Tiziana Life Sciences (NASDAQ:TLSA) reported positive results from a study of its nasal anti-CD3 antibody, foralumab, for non-active secondary progressive multiple sclerosis treatment.
- The company's stock is up 7.4%.
- The open-label study showed that foralumab was safe, triggered strong immune regulation, reduced brain inflammation, and helped slow disease progression in patients whose condition worsens without relapses.
- The company said that all participants saw their disability levels stabilize, and three out of four patients treated for 12 months even showed improvement.
- When it came to safety, the study reported no serious or severe treatment-related adverse events.
More on Tiziana Life Sciences
- Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment
- Tiziana Life Sciences ticks up on IND submission for mid-stage trial of its ALS treatment
- Tiziana stock jumps 12% on TBI drug study publication
- Financial information for Tiziana Life Sciences
推薦文章
港股周報丨三家外賣平臺被約談！「瘋狂星期六」或不再瘋狂；花旗呼籲增持中國互聯網、科技及消費板塊
美股機會日報 | 特朗普放大招！9萬億養老金即將殺入加密市場；美聯儲主席候選人支持7月降息
一周財經日曆 | 特斯拉、谷歌財報重磅來襲！維立志博將於下周五登陸港交所
一圖看懂 | 港股上半年IPO募資額登頂全球！中籤就賺一萬港幣的「大肉籤」你參與了嗎？
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
創新葯行情徹底爆發！維立志博-B打新半日孖展超購130倍，凍資近150億港元
新股申購 | 維立志博-B入場費3535.30港元！引入騰訊、易方達等基石投資者
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
